| Li, Jing |
BRAVO, NCT05647915: Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD |
|
|
| Completed | 4 | 337 | RoW | Berberine plus lifestyle intervention, Placebo plus lifestyle intervention | China National Center for Cardiovascular Diseases | Obesity, Obesity, Abdominal, NAFLD | 08/24 | 08/24 | | |
NCT06425120: Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease |
|
|
| Not yet recruiting | 4 | 240 | RoW | Xuesaitong Soft Capsule, LixuwangⓇ, Placebo | China National Center for Cardiovascular Diseases | Coronary Heart Disease | 12/24 | 12/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT05965284: Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) |
|
|
| Recruiting | 4 | 40 | RoW | Azathioprine, Telitacicept, Taiai for commercial name | Chinese SLE Treatment And Research Group | ANCA-associated Vasculitis, Maintenance Therapy | 12/25 | 12/26 | | |
ABCD, NCT05749874: Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus |
|
|
| Not yet recruiting | 4 | 6500 | RoW | Berberine plus lifestyle intervention, Placebo plus lifestyle intervention | China National Center for Cardiovascular Diseases | PreDiabetes, Abdominal Obesity, Hypertension, Dyslipidemias | 12/26 | 12/26 | | |
NCT05962840: Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) |
|
|
| Recruiting | 4 | 40 | RoW | Telitacicept, Taiai for commercial name, Placebo of Telitacicept | Chinese SLE Treatment And Research Group, Peking Union Medical College Hospital | ANCA Associated Vasculitis | 12/26 | 12/26 | | |
EHTASEOCCS, NCT03373058: Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery |
|
|
| Recruiting | 3 | 310 | RoW | Hyperthermic Intraperitoneal Chemotherapy, HIPEC, cytoreductive surgery, CRS, adjuvant chemotherapy, ACT | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Henan Provincial People's Hospital, Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Cancer Hospital of Guizhou Province, Chinese PLA General Hospital, Hebei Medical University Fourth Hospital, The Second Hospital of Hebei Medical University, West China Second University Hospital, Peking Union Medical College Hospital, First Affiliated Hospital, Sun Yat-Sen University, Henan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, The Third Affiliated Hospital of Guangzhou Medical University, Wuhan University, RenJi Hospital, Obstetrics & Gynecology Hospital of Fudan University, Southern Medical University, China, Fourth Affiliated Hospital of Guangxi Medical University, Shandong Cancer Hospital and Institute, Beijing Obstetrics and Gynecology Hospital, Chongqing University Cancer Hospital, Xinqiao Hospital of Chongqing, Wuhan Union Hospital, China, First Affiliated Hospital of Chongqing Medical University, Affiliated Cancer Hospital of Shantou University Medical College | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 07/21 | 07/23 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
Be-CLEVER, NCT05976152: Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial |
|
|
| Recruiting | 3 | 3200 | RoW | dl-3-butylphthalide, DL-3-n-butylphthalide (NBP), dl-3-butylphthalide placebo, NBP placebo | Fudan University | Stroke, Post-stroke Cognitive Impairment (PSCI) | 12/26 | 12/26 | | |
NCT01592968: Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases |
|
|
| Active, not recruiting | 3 | 88 | US | Cognitive Assessment, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain | 09/25 | 09/25 | | |
NHIPEC, NCT05246020: Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the Trial) |
|
|
| Recruiting | 2 | 80 | RoW | HIPEC, intravenous chemotherapy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hyperthermic Intraperitoneal Chemotherapy, Neoadjuvant Chemotherapy | 12/22 | 12/24 | | |
NCT02713269: Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients with Spine Metastases At Risk for Compressing the Spinal Cord |
|
|
| Active, not recruiting | 2 | 60 | US | Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Thermal Ablation Therapy, thermal ablation | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC V6 and V7, Stage IV Lung Non-Small Cell Cancer AJCC V7, Thyroid Gland Carcinoma | 08/25 | 08/25 | | |
NCT06205927: Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 77 | RoW | Standard carbon ion beam radiotherapy, Carbon ion beam radiotherapy simultaneously dose boost | Jian Chen | Non-small Cell Lung Cancer | 12/24 | 12/26 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT06186726: Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors |
|
|
| Recruiting | 2 | 48 | RoW | carbon ion radiotherapy | Jian Chen | Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy | 12/26 | 12/29 | | |
NCT06311981: Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients |
|
|
| Recruiting | 2 | 29 | RoW | carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy | Jian Chen | Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect | 06/25 | 06/26 | | |
NCT06311955: Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor |
|
|
| Recruiting | 2 | 48 | RoW | Carbon ion radiotherapy, combined with platinum-based regimen | Jian Chen | Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy | 02/28 | 02/29 | | |
NCT06311968: The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor |
|
|
| Recruiting | 2 | 55 | RoW | Proton radiotherapy, combined platinum based chemotherapy | Jian Chen | Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity | 02/27 | 02/27 | | |
| Not yet recruiting | 2 | 120 | RoW | Metformin Hydrochloride tablet, Metformin, Placebo | Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China | Metformin, Aging | 09/26 | 07/28 | | |
| Active, not recruiting | 2 | 49 | US | Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Clinical Stage IV Cutaneous Melanoma AJCC V8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC V8 | 08/26 | 08/26 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
NCT04516070: Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis |
|
|
| Active, not recruiting | 2 | 55 | US | Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 | 12/26 | 12/26 | | |
NCT05613452: Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 43 | RoW | Carbon ion beam radiotherapy | Shanghai Proton and Heavy Ion Center | Non-small Cell Lung Cancer | 01/25 | 01/26 | | |
NCT06036966: The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients |
|
|
| Not yet recruiting | 2 | 34 | NA | Hetrombopag | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Thrombocytopenia | 07/25 | 07/25 | | |
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 381 | RoW | Fruquintinib in Combination with Sintilimab, Fruquintinib | Hutchmed | Advanced Solid Tumor | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 180 | RoW | MG-K10, Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Asthma | 12/23 | 06/24 | | |
NCI-2016-00661, NCT02696993: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 80 | US | Cognitive Assessment, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy | M.D. Anderson Cancer Center | Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7 | 12/24 | 12/24 | | |
NCT04592458: Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients |
|
|
| Not yet recruiting | 1 | 10 | RoW | β-globin restored autologous HSC | BGI-research, Shenzhen Children's Hospital | β-Thalassemia Major | 11/22 | 11/24 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
NCT04682795: Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM |
|
|
| Recruiting | N/A | 200 | RoW | Needle-free injector, Insulin pen | Second Affiliated Hospital, School of Medicine, Zhejiang University | T2DM (Type 2 Diabetes Mellitus), Needle-free Injector, Time in Range | 12/22 | 12/22 | | |
ESPRIT, NCT04030234: Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs () Study |
|
|
| Completed | N/A | 11255 | RoW | Intensive BP treatment group, Control of SBP to <120 mmHg, Standard BP treatment group, Control of SBP to <140 mmHg | China National Center for Cardiovascular Diseases | Hypertension | 06/23 | 07/23 | | |
NCT05352633: Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study |
|
|
| Not yet recruiting | N/A | 710 | RoW | Intensive BP Arm, Control of SBP to <120 mmHg, Standard BP Arm, Control of SBP to <140 mmHg | China National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China | Blood Pressure | 09/23 | 09/23 | | |
PERFECT, NCT06181552: Development of CV Risk Prediction Tools Based on AI and Fundus Imaging Technology Study |
|
|
| Not yet recruiting | N/A | 1072 | NA | fundus photograpgy, optical coherence tomography, OCT, optical coherence tomography angiography, OCT-A | China National Center for Cardiovascular Diseases, Beijing Tongren Hospital | Cardiovascular Diseases | 03/25 | 06/25 | | |
FUTURE, NCT05459519: Effects of Dengzhanxixin Capsule on Platelet Function in Individuals at High Risk for Cardiovascular Disease |
|
|
| Recruiting | N/A | 165 | RoW | Dengzhanxixin Capsule plus Placebo Capsule, Placebo | China National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medial Sciences, Shenzhen, Shenzhen | Diabetes, Hypertension, Hypercholesterolemia | 12/23 | 12/23 | | |
NCT05722275: Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics |
|
|
| Recruiting | N/A | 400 | Europe, RoW | Peritoneal metastasis status ascertainment | Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Zhenjiang First People's Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital of Southern Medical University, Guizhou Provincial People's Hospital, Henan Cancer Hospital, Yunnan Cancer Hospital, Guangdong Provincial People's Hospital, Guangzhou Medical University, Fujian Medical University Union Hospital, Shanxi Province Cancer Hospital, Sun Yat-sen University, Beihang University, Scientific Institute San Raffaele | Gastric Cancer, Peritoneal Metastases | 12/23 | 12/28 | | |
NCT06422052: Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms |
|
|
| Recruiting | N/A | 2242 | RoW | Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD） | Shanghai Jiao Tong University School of Medicine | Helicobacter Pylori Infection, Dyspepsia | 05/25 | 05/25 | | |
NutriConnect, NCT06263751: Comparing the Effectiveness of Two Produce Prescription Approaches On Fruit and Vegetable Intake and Food Security, While Exploring Implementation Outcomes Such as Reach, Implementation, Sustainability, and Cost |
|
|
| Recruiting | N/A | 240 | US | Product prescription program- NutriConnect Credit, Product prescription program- NutriConnect Delivery | Washington University School of Medicine, Schnuck Markets, Inc., BJC HealthCare | Food Insecurity | 03/25 | 06/25 | | |
NCT06163092: Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage |
|
|
| Not yet recruiting | N/A | 175 | RoW | | Chinese University of Hong Kong | Recurrent Miscarriage | 01/26 | 01/27 | | |
NCT05783986: Developing a MRI-based Deep Learning Model to Predict MMR Status |
|
|
| Not yet recruiting | N/A | 600 | NA | randomly divided | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University | Endometrial Cancer | 06/24 | 12/24 | | |
NCT06622798: Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients |
|
|
| Recruiting | N/A | 470 | RoW | Non-interventional | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Amoy Diagnostics Co., LTD | Exploring the Correlation of HRD Score Pairs with the Prognosis of Chinese Ovarian Cancer Patients and the Outcome of Maintenance Therapy with PARPi | 01/25 | 07/26 | | |
NCT06035250: AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy |
|
|
| Recruiting | N/A | 200 | Europe, RoW | Neoadjuvant Chemotherapy | Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Yunnan Cancer Hospital, Henan Cancer Hospital, Zhenjiang First People's Hospital, First Hospital of China Medical University, Cancer Hospital of Guangxi Medical University, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital, Southern Medical University, The Affiliated Hospital of Qingdao University, Ruijin Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Peking Union Medical College Hospital, Xiangya Hospital of Central South University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Soochow University, First Affiliated Hospital, Sun Yat-Sen University, Fujian Medical University Union Hospital, Fujian Cancer Hospital, San Raffaele University Hospital, Italy | Gastric Cancer, Image, Pathology | 08/24 | 12/29 | | |
| Recruiting | N/A | 216 | RoW | Baduanjin, Brisk walking | China National Center for Cardiovascular Diseases | Elevated Blood Pressure | 12/24 | 12/25 | | |
NCT05570071: A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI. |
|
|
| Not yet recruiting | N/A | 90 | NA | physical therapy | Qianfoshan Hospital | Urinary Incontinence, Stress | 03/25 | 03/25 | | |
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments |
|
|
| Recruiting | N/A | 50 | RoW | | Jing Li, Nanjing Shihejiyin Technology, Inc. | Ovarian Cancer Stage IV, Ovarian Cancer Stage III | 08/25 | 08/25 | | |
CHAPERONE, NCT05965115: The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The Study |
|
|
| Recruiting | N/A | 10000 | RoW | Sample of Blood | Shanghai Zhongshan Hospital | Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance | 08/25 | 08/35 | | |
NCT05613049: Confounding Factors of Chronic Endometritis in Women With Reproductive Failure |
|
|
| Recruiting | N/A | 720 | RoW | | Chinese University of Hong Kong | IVF | 07/27 | 01/28 | | |
NCT05153603: Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting |
|
|
| Not yet recruiting | N/A | 50 | NA | Olaparib mono-maintenance therapy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Ovarian Neoplasms | 09/22 | 12/22 | | |
| Not yet recruiting | N/A | 300 | NA | Neonatal hyperbilirubinemia | Shanghai First Maternity and Infant Hospital | Jaundice, Neonatal | 09/22 | 09/22 | | |
| Zhang, Li |
NCT05138705: Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years |
|
|
| Completed | 4 | 380 | RoW | Quadrivalent Influenza Virus Split Vaccine | Shanghai Institute Of Biological Products | Influenza, Human | 02/22 | 08/22 | | |
NCT03986528: Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 4 | 334 | RoW | Kanglaite Injection+Chemotherapy, Chemotherapy | Jie Li, Ministry of Science and Technology of the People´s Republic of China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences | NSCLC | 03/22 | 05/22 | | |
NCT05329038: Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine |
|
|
| Active, not recruiting | 4 | 180 | RoW | Inactivated COVID-19 Vaccine, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 06/22 | 02/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
FL-ALTER, NCT04028778: Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC |
|
|
| Recruiting | 3 | 310 | RoW | Gefitinib, Iressa, Anlotinib Hydrochloride, Placebo | Sun Yat-sen University | Lung Cancer, Nonsmall Cell | 12/20 | 12/22 | | |
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study |
|
|
| Not yet recruiting | 3 | 352 | RoW | olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen | Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | 02/21 | 03/21 | | |
NCT04550949: To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors |
|
|
| Recruiting | 3 | 700 | RoW | QL1206, recombinant human anti-RANKL monoclonal antibody injection, Xgeva, Denosumab Injection | Qilu Pharmaceutical Co., Ltd. | Bone Metastases | 03/21 | 06/22 | | |
RATIONALE 309, NCT03924986: Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC) |
|
|
| Completed | 3 | 263 | RoW | Tislelizumab, BGB-A317, Placebo, Gemcitabine, Cisplatin | BeiGene | Recurrent or Metastatic Nasopharyngeal Cancer | 03/21 | 12/23 | | |
|
|
|
|
|
NCT03707509: Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 263 | RoW | Camrelizumab, SHR-1210, Placebos, Placebo - Concentrate, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplantin Injection | Jiangsu HengRui Medicine Co., Ltd. | Nasopharyngeal Carcinoma | 08/21 | 12/22 | | |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
ORIENT-11, NCT03607539: Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC |
|
|
| Completed | 3 | 397 | RoW | Sintilimab, IBI308, Pemetrexed, Platinum, Placebos | Innovent Biologics (Suzhou) Co. Ltd. | Lung Neoplasms | 02/23 | 02/23 | | |
|
|
|
|
|
|
|
PROFIT, NCT05509634: Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors |
|
|
| Completed | 3 | 754 | RoW | HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone | Fujian Shengdi Pharmaceutical Co., Ltd. | Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy | 06/23 | 08/23 | | |
NCT05683600: Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older |
|
|
| Terminated | 3 | 3000 | RoW | Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, Placebo | Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd. | COVID-19 | 07/23 | 07/23 | | |
NCT04951648: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation |
|
|
| Not yet recruiting | 3 | 220 | RoW | Almonertinib, HS-10296, chemotherapy | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 10/23 | 09/24 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations |
|
|
| Not yet recruiting | 3 | 398 | NA | JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection | Shanghai JMT-Bio Inc. | Local Advanced or Metastatic NSCLC | 03/27 | 03/28 | | |
BL-B01D1-301, NCT06382116: A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 428 | RoW | BL-B01D1, Pemetrexed+Cisplatin or Carboplatin | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 05/26 | 05/26 | | |
| Not yet recruiting | 3 | 8862 | RoW | Colchicine 0.5 mg, no other name, Colchicine 0.375 mg, Placebo | Wuhan Union Hospital, China | Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine | 03/28 | 08/28 | | |
| Recruiting | 3 | 652 | RoW | BL-B01D1, Topotecan | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Small Cell Lung Cancer | 07/26 | 07/26 | | |
NCT06554184: HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents |
|
|
| Recruiting | 3 | 700 | RoW | HR20013 + dexamethasone + palonosetron placebo, Palonosetron + dexamethasone + HR20013 placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents | 09/25 | 09/25 | | |
NCT06735391: A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations |
|
|
| Recruiting | 3 | 516 | RoW | JMT101, Recombinant Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Injection, Osimertinib | Shanghai JMT-Bio Inc. | Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC | 09/26 | 05/29 | | |
NCT06082635: TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 297 | RoW | TGRX-326, TGRX-326 QD (once a day), Crizotinib, Crizotinib 250 mg BID (twice a day) | Shenzhen TargetRx, Inc., Sun Yat-sen University | Non Small Cell Lung Cancer | 12/24 | 11/28 | | |
| Active, not recruiting | 3 | 322 | RoW | Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection | Akeso, Akeso | Non-Squamous Non-small Cell Lung Cancer | 06/24 | 11/25 | | |
| Recruiting | 3 | 356 | RoW | SKB264, Pemetrexed, Carboplatin, Cisplatin | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 05/25 | 09/26 | | |
| Not yet recruiting | 3 | 650 | NA | QL1706, PSB205, Tilesizumab, BGB-108 | Qilu Pharmaceutical Co., Ltd. | Lung Cancer | 06/25 | 06/25 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
NCT06118333: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 368 | RoW | BL-B01D1, capecitabine, gemcitabine, docetaxel | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | 12/25 | 12/25 | | |
NCT05943795: A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 584 | RoW | SI-B001, Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung | 07/26 | 07/26 | | |
NCT06319313: Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2/3 | 534 | NA | JMT101, docetaxel, HB1801 | Shanghai JMT-Bio Inc. | Squamous Cell Non-small Cell Lung Cancer | 07/26 | 12/27 | | |
NCT05020769: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. |
|
|
| Recruiting | 2/3 | 14 | RoW | SI-B001, Osimertinib | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
DUBHE-N-302, NCT05576272: A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2/3 | 460 | RoW | QL1706, Carrelizumab, Gemcitabine, Cisplatin | Qilu Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | 12/24 | 12/24 | | |
SURPASS, NCT05623267: Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT |
|
|
| Recruiting | 2/3 | 346 | RoW | Sugemalimab, Placebo | Sun Yat-sen University | Limited Stage Small Cell Lung Cancer | 12/25 | 03/27 | | |
NCT03215693: X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib |
|
|
| Active, not recruiting | 2 | 152 | RoW | X-396 capsule, Ensartinib | Betta Pharmaceuticals Co., Ltd. | Non-Small Cell Lung Cancer | 03/20 | 12/23 | | |
NCT04102982: Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer |
|
|
| Recruiting | 2 | 200 | RoW | Camrelizumab, Camrelizumab plus microwave ablation, Camrelizumab plus MWA | Shandong Provincial Hospital | NSCLC Stage IV | 10/21 | 02/22 | | |
NCT04164745: Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 49 | RoW | Anlotinib, oral capsule, Pembrolizumab | Peking Union Medical College Hospital | NSCLC | 11/21 | 11/22 | | |
JMT101-CSP-005, NCT06391944: JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations |
|
|
| Active, not recruiting | 2 | 161 | RoW | JMT101 Injection, Osimertinib tablet | Shanghai JMT-Bio Inc. | Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation | 05/23 | 11/26 | | |
| Recruiting | 2 | 54 | RoW | KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 05/27 | 12/27 | | |
NCT04453930: A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） |
|
|
| Recruiting | 2 | 60 | RoW | Camrelizumab，an engineered anti-PD-1 antibody, SHR-1210, Platinum, Irinotecan, Apatinib | Peking Union Medical College Hospital | Small Cell Lung Carcinoma | 06/23 | 06/23 | | |
NCT05162872: Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 99 | RoW | Niraparib，Sintilimab | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/23 | 10/23 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
| Recruiting | 2 | 110 | RoW | SKB264, KL-A167, Carboplatin, Cisplatin | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Non-small Cell Lung Cancer | 08/24 | 04/26 | | |
NCT04459663: JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. |
|
|
| Not yet recruiting | 2 | 50 | RoW | Toripalimab injection combine with Axitinib | Li Zhang, MD | Non-small Cell Lung Cancer | 09/23 | 12/23 | | |
BECOME, NCT05132777: Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 155 | NA | JMT101, Osimertinib Mesylate Tablets | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 09/23 | 09/24 | | |
NCT06165380: Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | Cardenilimab Combined With Chemotherapy | Li Zhang | Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies | 12/24 | 12/25 | | |
EAGLE, NCT05491811: Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation |
|
|
| Active, not recruiting | 2 | 49 | RoW | Ensartinib, Bevacizumab, MIL60 | Sun Yat-sen University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shenyang Chest Hospital, Hebei Medical University Fourth Hospital, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Guangzhou Institute of Respiratory Disease, Central People's Hospital of Zhanjiang, Guangdong Provincial Agricultural Reclamation Central Hospital, Wuhan Union Hospital, China, West China Hospital, The First Affiliated Hospital with Nanjing Medical University, Yuebei People's Hospital, Yunnan Cancer Hospital | Non-Small Cell Lung Cancer | 08/24 | 12/26 | | |
GASTO-1091, NCT04085250: Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy |
|
|
| Active, not recruiting | 2 | 264 | RoW | Neoadjuvant therapy, Chemotherapy concurrent with radiotherapy, Radiotherapy, Nivolumab, Observation | Sun Yat-sen University | Stage III Non-small-cell Lung Cancer | 01/25 | 01/25 | | |
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. |
|
|
| Completed | 2 | 34 | RoW | Chidamide, CS055, Envafolimab, KN035 | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 02/23 | 05/24 | | |
NCT05020457: SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. |
|
|
| Recruiting | 2 | 60 | RoW | SI-B001, AP or TP, AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin., Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 06/25 | 06/25 | | |
